EJIFCC最新文献_第4页

Professional Certification in Point-of-Care Testing. 护理点测试专业认证。

EJIFCC Pub Date : 2021-10-18 eCollection Date: 2021-10-01

T Scott Isbell, Elaine Colwell, Elizabeth L Frank, Brad S Karon, Veronica Luzzi, Lou Ann Wyer

引用次数: 0

Synergy Between Point-of-Care Testing and Laboratory Consolidations. 护理点检测和实验室合并之间的协同作用。

EJIFCC Pub Date : 2021-10-18 eCollection Date: 2021-10-01

Tommaso Trenti

{"title":"Synergy Between Point-of-Care Testing and Laboratory Consolidations.","authors":"Tommaso Trenti","doi":"","DOIUrl":"","url":null,"abstract":"Central or area laboratories will offer an improved number of diagnostic testing services, where drivers for change will involve chronic disease clinical care for an increasingly older population, new emerging diagnostic technologies and personalized medicine. Higher automation quality and ever more diagnostic field integration will lead to higher productivity by means of an improved throughput. At the same time Point of Care Testing (POCT) site of patient care allows for timely medical assessment, which can lead to improved patient outcomes, more effectiveness and patient satisfaction. POCT test introduction in clinical practice should be assessed by an outcome-based policy to avoid adverse events, failure to diagnose providing appropriate timed treatment. The use of POCT devices does not only require technological considerations for the production and management of acceptable tests possibly managed by central laboratory, but also implicates a shift in diagnostic practice across all health organizations. The interaction between laboratory professionals and clinicians will be enriched with new methods of evaluation of patient needs in the internet of things and mobile Health worlds, where boundaries between POCT and central laboratory or hospital and primary healthcare will no longer exist and where all data can be shared and disseminated among stakeholders in the healthcare system.","PeriodicalId":193105,"journal":{"name":"EJIFCC","volume":"32 3","pages":"328-336"},"PeriodicalIF":0.0,"publicationDate":"2021-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/94/ejifcc-32-328.PMC8592627.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39655859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Combined Analysis of Serum Growth Differentiation Factor-15 and Cancer Antigen 15-3 Enhances the Diagnostic Efficiency in Breast Cancer. 血清生长分化因子-15和肿瘤抗原15-3联合分析提高乳腺癌的诊断效率。

EJIFCC Pub Date : 2021-10-18 eCollection Date: 2021-10-01

Anupama Modi, Purvi Purohit, Ashita Gadwal, Dipayan Roy, Sujoy Fernandes, Jeewan Ram Vishnoi, Puneet Pareek, Poonam Elhence, Sanjeev Misra, Praveen Sharma

{"title":"A Combined Analysis of Serum Growth Differentiation Factor-15 and Cancer Antigen 15-3 Enhances the Diagnostic Efficiency in Breast Cancer.","authors":"Anupama Modi, Purvi Purohit, Ashita Gadwal, Dipayan Roy, Sujoy Fernandes, Jeewan Ram Vishnoi, Puneet Pareek, Poonam Elhence, Sanjeev Misra, Praveen Sharma","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Existing diagnostic biomarkers of breast cancer (BC) are limited by poor sensitivity. In this study, we evaluated the role of serum GDF-15 in early BC diagnosis, independently and in combination with CA15-3, a known blood biomarker of BC.Material and methods: A total of 113 diagnosed, pre-therapy BC patients and 54 healthy controls were recruited. Clinical characteristics, TNM staging, and hormone receptor status of the patients were recorded. Serum GDF-15 and serum CA15-3 were measured by sandwich ELISA and chemiluminescence assay, respectively.Results: The serum GDF-15 levels were significantly (p<0.001) elevated in BC patients compared to healthy controls and in patients with larger tumor size, advanced disease stage, and distant metastasis. ROC analysis revealed that at the cut-off of 525.77 pg/mL, GDF-15 had greater sensitivity than CA15-3. GDF-15 and CA15-3 performed better in combination than individually, with the combined test having an AUC of 0.85 and sensitivity and specificity of 0.63 and 0.98, respectively.Further, serum GDF-15 had a better predictive ability for early-stage BC compared to CA15-3. GDF-15 could independently diagnose BC patients after adjusting for age.Conclusion: We conclude that serum GDF-15 is a promising, robust marker for detecting early-stage BC. However, larger prospective studies are necessary to validate this claim.","PeriodicalId":193105,"journal":{"name":"EJIFCC","volume":"32 3","pages":"363-376"},"PeriodicalIF":0.0,"publicationDate":"2021-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/e0/ejifcc-32-363.PMC8592631.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39655862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Biomarkers in COVID-19: A Narrative Review. 2019冠状病毒病的心脏生物标志物:述评

EJIFCC Pub Date : 2021-10-18 eCollection Date: 2021-10-01

Giuseppe Lippi, Fabian Sanchis-Gomar, Brandon Michael Henry, Carl J Lavie

引用次数: 0

In-House Algorithm for Reporting Discrepant HbA1c Result and Troubleshooting a Case of False Low HbA1c. HbA1c结果不一致报告和假低HbA1c案例排除的内部算法。

EJIFCC Pub Date : 2021-10-18 eCollection Date: 2021-10-01

Vivek Pant, Abha Shrestha, Devish Pyakurel, Keyoor Gautam, Santosh Pradhan

引用次数: 0

Hope Injections: The Promises of Regenerative Medicine in Curing Type 1 Diabetes Mellitus. 希望注射:再生医学治疗1型糖尿病的承诺。

EJIFCC Pub Date : 2021-10-18 eCollection Date: 2021-10-01

Nina Maria Fanaropoulou

引用次数: 0

Clinicians' Probability Calculator to Convert Pre-Test to Post-Test Probability of SARS-CoV-2 Infection Based on Method Validation from Each Laboratory. 基于各实验室方法验证的临床医生将SARS-CoV-2感染检测前概率转换为检测后概率的概率计算器

EJIFCC Pub Date : 2021-06-29 eCollection Date: 2021-06-01

Zoe Brooks, Saswati Das, Tom Pliura

{"title":"Clinicians' Probability Calculator to Convert Pre-Test to Post-Test Probability of SARS-CoV-2 Infection Based on Method Validation from Each Laboratory.","authors":"Zoe Brooks, Saswati Das, Tom Pliura","doi":"","DOIUrl":"","url":null,"abstract":"Background: Despite best efforts, false positive and false negative test results for SARS-CoV-2 are unavoidable. Likelihood ratios convert a clinical opinion of pre-test probability to post-test probability, independently of prevalence of disease in the test population.Methods: The authors examined results of PPA (Positive Percent Agreement, sensitivity) and NPA (Negative Percent Agreement, specificity) from 73 laboratory experiments for molecular tests for SARS-CoV-2 as reported to the FIND database, and for two manufacturers' claims in FDA EUA submissions.PPA and NPA were converted to likelihood ratios to calculate post-test probability of disease based on clinical opinion of pre-test probability. Confidence intervals were based on the number of samples tested. An online calculator was created to help clinicians identify false-positive, or false-negative SARS-CoV-2 test results for COVID-19 disease.Results: Laboratory results from the same test methods did not mirror each other or the manufacturer. Laboratory studies showed PPA from 17% to 100% and NPA from 70.4% to 100%. The number of known samples varied 8 to 675 known patient samples, which greatly impacted confidence intervals.Conclusion: Post-test probability of the presence of disease (true-positive or false-negative tests) varies with clinical pre-test probability, likelihood ratios and confidence intervals.The Clinician's Probability Calculator creates reports to help clinicians estimate post-test probability of COVID-19 based on the testing laboratory's verified PPA and NPA.","PeriodicalId":193105,"journal":{"name":"EJIFCC","volume":"32 2","pages":"265-279"},"PeriodicalIF":0.0,"publicationDate":"2021-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/dc/ejifcc-32-265.PMC8343041.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39334136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Foreword: Introducing the eJIFCC Special Issue on "POCT - Making the Point". 前言:介绍“POCT - Making the Point”专题。

EJIFCC Pub Date : 2021-06-29 eCollection Date: 2021-06-01

Sergio Bernardini

引用次数: 0

Training and Competency Strategies for Point-of-Care Testing. 护理点测试的培训和能力策略。

EJIFCC Pub Date : 2021-06-29 eCollection Date: 2021-06-01

Sedef Yenice

{"title":"Training and Competency Strategies for Point-of-Care Testing.","authors":"Sedef Yenice","doi":"","DOIUrl":"","url":null,"abstract":"The increased availability and use of POCT are being influenced by many factors, such as; industry trends to move towards patient-centered care and healthcare decentralization, the increasing prevalence of infectious diseases also including the current use of Rapid SARS-CoV-2 Testing, a growing incidence of lifestyle diseases such as diabetes, heart disease, and hypertension, as well as advances in in-vitro diagnostic medical technologies. The use of POCT can increase the efficiency of services and improve outcomes for patients. However, the variability of the testing environment and conditions as well as the competency of staff performing the tests may have a significant impact on the quality and accuracy of POCT results. A majority of the staff who perform POCT are not trained laboratory staff and may not be as knowledgeable about the processes involved in testing, such as patient preparation, sample collection, management of equipment and supplies, instrument calibration and maintenance, the performance of the test, quality control, interpretation of the results, and reporting/documentation of results in each patient's context. Therefore, staff performing POCT must have the proper training and experience to ensure test results are accurate and reliable. This short communication outlines the specific requirements for staff training based on international standards which need to be considered to ensure the quality of test results and describes competency criteria required for compliance with POCT.","PeriodicalId":193105,"journal":{"name":"EJIFCC","volume":"32 2","pages":"167-178"},"PeriodicalIF":0.0,"publicationDate":"2021-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/a0/ejifcc-32-167.PMC8343045.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39336223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leading POCT Networks: Operating POCT Programs Across Multiple Sites Involving Vast Geographical Areas and Rural Communities. 领先的POCT网络:在涉及广大地理区域和农村社区的多个站点运行POCT项目。

EJIFCC Pub Date : 2021-06-29 eCollection Date: 2021-06-01

Edward W Randell, Vinita Thakur

引用次数: 0